JP2005501031A - 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における２，５−ジヒドロキシベンゼンスルホン酸誘導体の使用 - Google Patents
勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における２，５−ジヒドロキシベンゼンスルホン酸誘導体の使用 Download PDFInfo
- Publication number
- JP2005501031A JP2005501031A JP2003510106A JP2003510106A JP2005501031A JP 2005501031 A JP2005501031 A JP 2005501031A JP 2003510106 A JP2003510106 A JP 2003510106A JP 2003510106 A JP2003510106 A JP 2003510106A JP 2005501031 A JP2005501031 A JP 2005501031A
- Authority
- JP
- Japan
- Prior art keywords
- effects
- enhance
- compounds
- penile
- nitric oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 10
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical class OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 title claims description 3
- 229940079593 drug Drugs 0.000 title description 2
- 201000001881 impotence Diseases 0.000 title description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002840 nitric oxide donor Substances 0.000 claims abstract description 10
- 230000018052 penile erection Effects 0.000 claims abstract description 9
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims abstract description 8
- 229960004046 apomorphine Drugs 0.000 claims abstract description 8
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims abstract description 7
- 239000011575 calcium Substances 0.000 claims description 8
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 claims description 6
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical group CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 229940011899 ethamsylate Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract description 16
- 229960003310 sildenafil Drugs 0.000 abstract description 8
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000006 Nitroglycerin Substances 0.000 abstract description 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract description 3
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 abstract description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract description 3
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002497 nicorandil Drugs 0.000 abstract description 3
- -1 nitroprusate Chemical compound 0.000 abstract description 3
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 abstract description 3
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002381 vardenafil Drugs 0.000 abstract description 3
- FDCLIBRKVBYTMQ-UHFFFAOYSA-N OC1(CC=CC(=C1)O)S(=O)(=O)O Chemical class OC1(CC=CC(=C1)O)S(=O)(=O)O FDCLIBRKVBYTMQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 description 11
- 210000003899 penis Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 0 Cc(cc(*)c(O)c1)c1S(O)(=O)=O Chemical compound Cc(cc(*)c(O)c1)c1S(O)(=O)=O 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- XYUSESXYUHHDPC-UHFFFAOYSA-N diethylazanium;2,5-dihydroxybenzene-1,4-disulfonate Chemical compound CC[NH2+]CC.CC[NH2+]CC.OC1=CC(S([O-])(=O)=O)=C(O)C=C1S([O-])(=O)=O XYUSESXYUHHDPC-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200101535A ES2180446B1 (es) | 2001-07-02 | 2001-07-02 | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
| PCT/ES2002/000325 WO2003004097A1 (es) | 2001-07-02 | 2002-07-01 | Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005501031A true JP2005501031A (ja) | 2005-01-13 |
| JP2005501031A5 JP2005501031A5 (https=) | 2006-01-05 |
Family
ID=8498259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003510106A Pending JP2005501031A (ja) | 2001-07-02 | 2002-07-01 | 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における２，５−ジヒドロキシベンゼンスルホン酸誘導体の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20040143010A1 (https=) |
| EP (1) | EP1413332B1 (https=) |
| JP (1) | JP2005501031A (https=) |
| AR (1) | AR036124A1 (https=) |
| AT (1) | ATE419012T1 (https=) |
| BR (1) | BR0211315A (https=) |
| CA (1) | CA2453572A1 (https=) |
| DE (1) | DE60230629D1 (https=) |
| ES (2) | ES2180446B1 (https=) |
| HU (1) | HUP0400924A3 (https=) |
| MX (1) | MXPA04000007A (https=) |
| NO (1) | NO20040007L (https=) |
| PL (1) | PL367766A1 (https=) |
| WO (1) | WO2003004097A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2208123A1 (es) * | 2002-11-29 | 2004-06-01 | Laboratorios Del Dr. Esteve, S.A. | Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento. |
| ES2222831B2 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
| RU2281101C2 (ru) * | 2004-10-01 | 2006-08-10 | Юрий Михайлович Есилевский | Способ лечения больных хроническим простатитом |
| EP1676573A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
| ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
| CA2771389C (en) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
| CN109678764A (zh) * | 2018-12-05 | 2019-04-26 | 湖北广辰药业有限公司 | 一种羟苯双磺酸及其钙盐和制备方法 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681503A (en) * | 1970-04-17 | 1972-08-01 | Om Lab Sa | Method for combating disturbances of the lipid content of the blood |
| US4252821A (en) * | 1979-12-07 | 1981-02-24 | Laboratoires Om Societe Anonyme | Method for treating ulcers |
| US4511557A (en) * | 1981-08-24 | 1985-04-16 | Gauri Kailash Kumar | Pharmaceutical composition |
| US4513007A (en) * | 1983-05-03 | 1985-04-23 | Laboratoires Om Sa | Method for treating heart disease |
| RU1776408C (ru) * | 1990-08-13 | 1992-11-23 | Одесский Медицинский Институт Им.Н.И.Пирогова | Способ лечени гломерулонефрита |
| JP2000508308A (ja) * | 1996-04-03 | 2000-07-04 | ラボラトリオス デル ドクトール エステベ，エス．アー． | 内皮機能の正常化、性的機能障害、糖尿病の血管合併症及び内皮起源の血管障害の治療用の医薬の製造のための２，５―ジヒドロキシベンゼンスルホン酸誘導体の使用 |
| HU225149B1 (en) * | 1996-12-30 | 2006-07-28 | Teva Gyogyszergyar Zrt | Use of dobesilate salts for the manufacture of medicaments for the treatment or prevention of embryonic retardation or discordance |
| US6403643B1 (en) * | 1997-04-03 | 2002-06-11 | Laboratories Del Dr. Esteve, S.A. | Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function |
| US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
-
2001
- 2001-07-02 ES ES200101535A patent/ES2180446B1/es not_active Expired - Fee Related
-
2002
- 2002-07-01 PL PL02367766A patent/PL367766A1/xx not_active Application Discontinuation
- 2002-07-01 AR ARP020102472A patent/AR036124A1/es not_active Application Discontinuation
- 2002-07-01 BR BR0211315-5A patent/BR0211315A/pt not_active IP Right Cessation
- 2002-07-01 WO PCT/ES2002/000325 patent/WO2003004097A1/es not_active Ceased
- 2002-07-01 HU HU0400924A patent/HUP0400924A3/hu unknown
- 2002-07-01 ES ES02745439T patent/ES2318023T3/es not_active Expired - Lifetime
- 2002-07-01 MX MXPA04000007A patent/MXPA04000007A/es not_active Application Discontinuation
- 2002-07-01 DE DE60230629T patent/DE60230629D1/de not_active Expired - Fee Related
- 2002-07-01 EP EP02745439A patent/EP1413332B1/en not_active Expired - Lifetime
- 2002-07-01 CA CA002453572A patent/CA2453572A1/en not_active Abandoned
- 2002-07-01 US US10/482,457 patent/US20040143010A1/en not_active Abandoned
- 2002-07-01 AT AT02745439T patent/ATE419012T1/de not_active IP Right Cessation
- 2002-07-01 JP JP2003510106A patent/JP2005501031A/ja active Pending
-
2004
- 2004-01-02 NO NO20040007A patent/NO20040007L/no not_active Application Discontinuation
-
2006
- 2006-12-19 US US11/641,269 patent/US20070197543A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070197543A1 (en) | 2007-08-23 |
| HUP0400924A2 (hu) | 2004-07-28 |
| CA2453572A1 (en) | 2003-01-16 |
| WO2003004097A1 (es) | 2003-01-16 |
| NO20040007L (no) | 2004-02-23 |
| EP1413332A1 (en) | 2004-04-28 |
| ES2318023T3 (es) | 2009-05-01 |
| ES2180446B1 (es) | 2004-01-16 |
| BR0211315A (pt) | 2004-09-28 |
| EP1413332B1 (en) | 2008-12-31 |
| DE60230629D1 (de) | 2009-02-12 |
| MXPA04000007A (es) | 2004-05-21 |
| US20040143010A1 (en) | 2004-07-22 |
| ATE419012T1 (de) | 2009-01-15 |
| PL367766A1 (en) | 2005-03-07 |
| HUP0400924A3 (en) | 2007-11-28 |
| ES2180446A1 (es) | 2003-02-01 |
| AR036124A1 (es) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6265420B1 (en) | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide | |
| JP2005501031A (ja) | 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における２，５−ジヒドロキシベンゼンスルホン酸誘導体の使用 | |
| CN101107039A (zh) | 递送治疗性金属离子、合金以及盐的方法 | |
| EA200401303A1 (ru) | Лекарственные средства, содержащие стероиды и новое антихолинергическое средство | |
| MX2022009081A (es) | Absorcion celular. | |
| Amadi et al. | Thyroid hormone: the modulator of erectile function in the rabbit. | |
| Amiri et al. | Removal of thallium by combining desferrioxamine and deferiprone chelators in rats | |
| CN104324018B (zh) | 广藿香醇在制备男性性功能障碍药物或保健品中的应用 | |
| RU2446483C1 (ru) | Способ моделирования интерорецепторного термического ожогового шока нехирургическим путем в остром эксперименте | |
| SU886907A1 (ru) | Способ лечени ожогов | |
| Dorland | The American Illustrated Medical Dictionary: A New and Complete Dictionary of the Terms Used in Medicine, Surgery, Dentistry, Pharmacy, Chemistry, and the Kindred Branches, with Their Pronunciation, Derivation and Definition | |
| RU2317072C1 (ru) | Способ подготовки спермы для внутриматочной инсеминации | |
| KR100324447B1 (ko) | 아티파메졸을 함유하는 남성 성기능 장애 치료용 약학적 조성물 | |
| Lyon et al. | Promotion of Healing by Benzoyl Peroxide and Other Agents. | |
| Newcomer et al. | Unique wounds and wound emergencies | |
| SABO et al. | THYROID HORMONE: THE MODULATOR OF ERECTILE FUNCTION IN THE RABBIT. | |
| RU2286126C1 (ru) | Способ коррекции эректильной дисфункции | |
| RU2002124680A (ru) | Способ эндоскопического лечения заболеваний желудочно-кишечного тракта | |
| Phillips | Materia Medica, Pharmacology, and Therapeutics: Inorganic Substances | |
| RU2200561C1 (ru) | Способ лечения и профилактики заболеваний | |
| RU2196590C1 (ru) | Средство гидросульфат углеродо-ртутный комплекс и способ лечения инфекционно-воспалительных заболеваний | |
| BR102022009993A2 (pt) | Composto polivalente de cura da covid-19 e de doenças causadas por quaisqueres microorganismos e prevenção de cânceres causados por radicais-livres (tanicina) | |
| McInturff | The Electroherbalism Frequency Lists | |
| CN103610676B (zh) | 4-((吡啶-3-羧基)-氨基)-丁酸或其盐在制备治疗男性性功能勃起障碍疾病药物中的应用 | |
| GUGGENHEIM et al. | Bone Fistula: Further Studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090811 |